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Background: Lipid-emulsion propofol (LP) has cardioprotective effects against ischemia-reperfusion injury, but 
it has lipid-related side effects. Microemulsion propofol (MP) is a lipid-free propofol emulsified with 10% purified 
poloxamer 188 (PP188). PP188 is a nonionic surfactant and has cardioprotective effects. However, some reports 
have suggested that reduced cardioprotective effects were observed when the cardioprotective agents were used in 
combination even though each cardioprotective agent has cardioprotective effects. The aims of this study were to 
examine and compare the cardioprotective effects of MP and LP. 
Methods: 50 isolated rat hearts were perfused with modified Kreb’s solution. They were divided into 4 groups 
and underwent 30 minutes of ischemia and 60 minutes of reperfusion. Control group: ischemia-reperfusion was 
performed without treatment. LP, MP and PP groups: LP, MP and PP188 were infused during the pre-ischemic and 
reperfusion period, respectively. Hemodynamic parameters and coronary effluent flow rate (CEFR) were measured. 
Infarct size was determined using triphenyl-tetrazolium staining.
Results: In the MP group, systolic pressure was maintained near baseline, the systolic pressure was higher than 
that in the other groups and HR was lower than that in the other groups during reperfusion. Diastolic pressure was 
transiently increased in the PP group after treatment and at 5 minutes after reperfusion compared with that in the 
control group and in the the LP group. There were no differences in dP/dtmax and CEFR between groups. Infarct size 
in the LP, MP and PP groups was smaller than that in the control group, but there were no significant differences 
between these three groups.
Conclusions: MP has cardioprotective effects similar to those of LP. MP can be used for cardiac anesthesia in cases 
with ischemia-reperfusion injury to avoid the lipid-related side effects of LP. (Korean J Anesthesiol 2012; 62: 358-364)
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Introduction
Extracorporeal circulation is required in cardiac trans-
plantation or in open heart surgery during which the heart 
undergoes artificial ischemia and reperfusion, which play an 
important role in reperfusion injuries including reversible 
myocardial stunning and irreversible damage such as 
myocardial infarction. Although most of the general anesthetic 
drugs have negative inotropic effects, there are agents that 
have a cardioprotective effect in myocardial ischemia and 
reperfusion injury [1]. Particularly, propofol has been reported 
to have cardioprotective effects through reduction of free 
oxygen radicals [2] and calcium overload phenomenon [3]. 
In addition, propofol allows hemodynamic stability during 
anesthesia, and it has been widely used in cardiac surgery and 
for postoperative sedation in the intensive care unit. However, 
several lipid-associated problems such as hypertriglyceridemia, 
pulmonary embolism and extrinsic contamination due to rapid 
bacterial growth at room temperature, have been reported with 
the long-term use of lipid-emulsion propofol (LP: Diprivan
Ⓡ, 
AstraZeneca, London, UK) [4-6]. To eliminate these adverse 
effects of lipid-emulsion propofol, microemulsion propofol 
(MP: Aquafol
Ⓡ, Daewon Pharmaceutical Co., Ltd., Seoul, 
Korea) emulsified with hydrophilic polymer (10% purified 
poloxamer 188) was developed. Poloxamer 188 (PP188) is 
nontoxic surface-active agent that has cytoprotective effects. 
PP188 is incorporated into the lipid bilayers, thereby decreasing 
their susceptibility to oxidative stress and inflammation [7-
11]. Inhaled anesthetics, propofol, and PP188 provide cardio-
protection against ischemia and reperfusion injury via different 
mechanisms [11], but despite these distinct mechanisms 
several studies have demonstrated that no additive or superior 
protection was observed with the combination of these 
cardioprotective agents [12,13].
Previous studies mainly focused on pharmacokinetic and 
pharmacodynamic characteristics of MP, and MP demonstrated 
pharmacokinetic and pharmacodynamic properties similar 
to those of LP [14]. However, the difference between LP and 
MP in terms of myocardial protection against ischemia and 
reperfusion injury during cardiac surgery is unknown.
The purpose of this study was to compare the myocardial 
protective effects between LP and MP emulsified with PP188 
by measuring hemodynamic parameters and infarct size in 
Langendorff perfused rat hearts.
Materials and Methods
This experimental study was approved by Institutional 
Animal Care and Use Committee. Male Sprague-Dawley rats 
(250-350 g) were allowed access to food and water until the 
day of surgery. Rats were anesthesized with pentobarbital (25-
30 mg, intraperitoneally). After confirming the loss of light 
reflex and responsiveness, rats were heparinized with sodium 
heparin (250 IU, intraperitoneally) and were intubated with a 
16G catheter via tracheostomy. Ventilation was maintained with 
animal ventilator (SN-480-7, Shinano Co., Nagano, Japan) with 
mixed gas (oxygen 95%, carbon dioxide 5%) at a respiratory 
rate of 50 breaths per minutes and a tidal volume of 3-4 ml. 
After median sternotomy, heart was rapidly excised en bloc and 
then was immersed in ice-cold perfusion solution to prevent 
myocardial injury during the remaining procedure. All hearts 
(coronary arteries) were perfused retrogradely via the aorta 
on the Langendorff apparatus with modified Kreb’s solution 
containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 25 mM NaHCO3, 10 mM glucose, 1.9 mM CaCl2, and 
0.5 mM Na-EDTA. The perfusate solution was maintained at 
37 ± 0.2
oC using a thermostatically controlled water circulating 
system (GP-200, NESLAB Instrument Inc., USA) and was kept 
at pH 7.4 ± 0.02 with 3L/min mixed gas (oxygen 95%, carbon 
dioxide 5%). Perfusion pressure was maintained at 55 mmHg by 
a 75-cm high fluid column with an overflow pump (Masterflex, 
Cole-Parmer Instrument Co., USA), and was measured at 
the level of the aortic root via a pressure transducer. A 3 mm 
saline-filled latex balloon connected to the pressure transducer 
(Ohmeda P23XL transducer, Ohmeda, Oxnard, CA, USA) was 
inserted into the left ventricle through the mitral valve via a left 
atrial incision and balloon volume was adjusted to maintain a 
diastolic pressure of 10 mmHg after equilibration of the heart.
All hearts were perfused on Langendorff apparatus and were 
stabilized for about 30 minutes in order to obtain the baseline 
measurements. Each group received a sequential experimental 
protocol including pretreatment, global ischemia and reperfu-
sion. After stabilization, pretreatment was performed for 15 
Fig. 1. Experimental protocol. After stabilization, each group was 
subjected to a 15 minutes pre-treat period, 30 minutes of global 
ischemia and 60 minutes of reperfusion. Specific agents were applied 
to each group as follows: perfusate and mixed gas (95% O2 + 5% CO2) 
only for control group; mixed gas with perfusate containing 6 μg/
ml lipid-emulsion propofol for LP group; 6 μg/ml microemulsion 
propofol for MP group; 60 μg/ml poloxamer 188 for PP group. 
Hemodyamic variables were measured at after stabilization, after 
pre-treat period and 5, 30, 60 minutes after reperfusion started 
(Dashed arrows). After all processes were completed, triphenyl 
tetrazolium staining was performed to calculate infarct size.360 www.ekja.org
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minutes in each group (as described below). By blocking the 
perfusion towards the hearts, global ischemia was induced 
for 30 minutes and this was then followed by restarting the 
perfusion for 60 minutes. Experiments were conducted in the 
4 groups, the control group underwent pretreatment and 
reperfusion without any medication, and the LP, MP and PP 
groups were treated with LP, MP and PP188 (Lutrol
Ⓡ F68, 
Sigma-Aldrich Korea Ltd., Kyunggi-Do, Korea), respectively 
during the pretreatment time and reperfusion. Each group 
was placed in a random order by using block randomization 
(Fig. 1).
Using the pressure sensor, hemodynamic parameters were 
measured after stabilization (baseline), before ischemia (after 
pretreatment), and at 5, 30 and 60 minutes after reperfusion. 
These parameters were automatically stored in the computer 
using MP-100 system (Biopac
Ⓡ System Inc., Goleta, CA, USA) 
and Acknowledge software (MP 100 manager version 3.8.2, 
Biopac
Ⓡ system Inc., Goleta, CA, USA). A cannula was inserted 
into the coronary sinus to measure the coronary effluent flow 
rate. Coronary effluent flow rate was defined as the flow per 
minute at each measurement point.
Perfusion fluid containing LP and MP corresponding to 
6 μg/ml of propofol solution were used during pretreatment 
and reperfusion. Because MP contains 10% PP188, PP188 was 
diluted in the same way as MP which corresponded to 60 μg/ml 
of PP188 in the perfusion fluid.
After reperfusion, the hearts were perfused with cold cardio-
plegic solution and immersed in ice-cold perfusate to achieve 
cardiac arrest. Then the hearts were immediately frozen 
to -20
oC. Whole ventricular muscles were sliced at 2 mm 
intervals and stained with triphenyl tetrazolium. The slices were 
incubated for 10 minutes in 1% solution of buffered triphenyl 
tetrazolium (2, 3, 5-triphenyl tetrazolium chloride: C19H15ClN4, 
TTC) at 37
oC and then immersed in 10% buffered formaldehyde 
for 20 minutes. The stained slices were then placed between 
two sheets of glass with 1.7 mm shims at the corners for 
squashing the slices to a uniform thickness, and the size of the 
damaged and the whole part of the ventricular muscles were 
measured using UTHSCSA Image Tool, version 3.0 (S. Brent 
Dove, University of Texas Health Science Center in San Antonio, 
Texas, USA). Then the heart volume of the damaged heart and 
the entire heart volume were calculated and infarct size was 
determined as the ratio (%) of the heart volume of the damaged 
heart to the entire heart volume. 
A total of 50 hearts were prepared for this experiment. Among 
these, 6 extracted hearts were excluded due to a surgical error 
or inappropriate cardiac function until stabilization. Finally, 44 
hearts were included in the statistical analysis; the control group 
contained 14 hearts, the LP, MP and PP groups contained 10 
hearts, respectively.
All statistics were calculated using SigmaPlot for Windows 
version 12.0 (Systat Software, Inc., IL, USA). Data were subjected 
to one-way analysis of variance (ANOVA) and one-way repeated 
measures ANOVA, and if statistical significance was established, 
Fig. 2. The changes in the left ventricular end systolic pressure 
(LVESP). Values are expressed as mean ± SD. Control group: no 
treatment during pre-ischemic and reperfusion period, LP, MP and 
PP groups: lipid emulsion propofol, microemulsion propofol and 
PP188 were infused during pre-ischemic and reperfusion period, 
respectively. Baseline: immediately after stabilization, Tx: pre-
ischemic treatment, R5: at 5 minutes after reperfusion, R30: at 30 
minutes after reperfusion, R60: at 60 minutes after reperfusion. 
Probability value was indicated as follows; *P < 0.05 vs. baseline, 
†vs. Tx, 
‡vs. R5, 
§vs. R30, 
∥vs. control group, 
¶vs. LP group, **vs. MP 
group. In the control group and in the LP group, LVESP significantly 
decreased during the reperfusion period compared with baseline, 
however in the MP group there was no significant decrease in LVESP.
Fig. 3. The changes in the left ventricular end diastolic pressure 
(LVEDP). Values are expressed as mean ± SD. Control group: no 
treatment during pre-ischemic and reperfusion period, LP, MP and 
PP groups: lipid emulsion propofol, microemulsion propofol and 
PP188 were infused during pre-ischemic and reperfusion period, 
respectively. Baseline: immediately after stabilization, Tx: pre-
ischemic treatment, R5: at 5 minutes after reperfusion, R30: at 30 
minutes after reperfusion, R60: at 60 minutes after reperfusion. 
Probability value was indicated as follows; *P < 0.05 vs. baseline, 
†vs. Tx, 
‡vs. R5, 
§vs. R30, 
∥vs. control group, 
¶vs. LP group, **vs. MP 
group. LVEDP was significantly higher in the MP group than in the 
control group and in the LP group. At R5, in the PP group, LVEDP was 
significantly increased than that at baseline and at Tx.361 www.ekja.org
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values of the control group and those of the other groups were 
compared using Bonferroni t-test. For all studies, statistical 
significance was considered at P < 0.05.
Results
Left ventricular end systolic pressure (LVESP, Fig. 2)
In the control group and in the LP group, LVESP was decreased 
after 5 minutes, 30 minutes and 60 minutes of reper  fusion and the 
values were significantly lower compared to the baseline value 
(Control group: P < 0.001, LP group: P = 0.001). In contrast, the MP 
group did not show significant changes in LVESP (P = 0.307) 
and in the PP group LVESP was decreased after reperfusion 
compared to the baseline value but the difference was not 
statistically significant (P = 0.070). After 30 and 60 minutes of 
reperfusion, LVESP was significantly higher in the MP group 
and in the PP group than in the control group (at 40 minutes 
of reperfusion: P = 0.009, at 60 minutes of reperfusion: P = 
0.001).
Left ventricular end diastolic pressure (LVEDP, Fig. 3)
At 5 minutes of reperfusion, LVEDP was increased in the 
control group and in the PP group compared to the baseline 
value and LVEDP progressively decreased at 30 and 60 minutes 
of reperfusion (P < 0.001). In the LP group, LVEDP after 
reperfusion was maintained near baseline, and at 60 minutes 
of reperfusion, LVEDP was significantly decreased compared to 
the baseline value (P = 0.008). In the MP group also, LVEDP was 
maintained near baseline (P = 0.428). In the LP group and in 
the MP group, LVEDP was lower than that in the control group 
at 5 minutes of reperfusion (P < 0.001) and in the LP group, the 
LVEDP value was lower than that in the control group even at 30 
minutes of reperfusion (P = 0.003). 
Heart rate (HR, Fig. 4)
In the LP group, HR was decreased after pretreatment, but 
after reperfusion it was maintained near baseline (P = 0.032). 
In the MP group, HR was decreased after pretreatment and low 
values were continued during reperfusion (P < 0.001). In the 
PP group, HR was decreased only at 5 minutes of reperfusion (P 
= 0.002), and the HR values were higher than those in the MP 
group after pretreatment, at 30 and 60 minutes after reperfusion 
(P = 0.001, P < 0.001 and P = 0.021, respectively).
Left ventricular pressure development over time 
(dP/dtmax, Fig. 5)
At 5 min of reperfusion, dP/dtmax was significantly reduced 
than the baseline values of all 4 groups (Control group, PP188 
Fig. 4. The changes in heart rate (HR). Values are expressed as 
mean ± SD. Control group: no treatment during pre-ischemic 
and reperfusion period, LP group: lipid emulsion propofol was 
infused during pre-ischemic and reperfusion period, MP group: 
microemulsion propofol was infused during pre-ischemic and 
reperfusion period, PP group: PP188 was infused during pre-
ischemic and reperfusion period. Baseline: immediately after 
stabilization, Tx: pre-ischemic treatment, R5: at 5 minutes after 
reperfusion, R30: at 30 minutes after reperfusion, R60: at 60 minutes 
after reperfusion. Probability value was indicated as follows; *P < 
0.05 vs. baseline, 
†vs. Tx, 
‡vs. R5, 
§vs. R30, 
∥vs. control group, 
¶vs. 
LP group, **vs. MP group. In the MP group, HR was significantly 
reduced after reperfusion compared with that at the baseline.
Fig. 5. The changes in the maximum rate of change in left ventricular 
pressure (dP/dtmax). Values are expressed as mean ± SD. Control 
group: no treatment during pre-ischemic and reperfusion period, LP 
group: lipid emulsion propofol was infused during pre-ischemic and 
reperfusion period, MP group: microemulsion propofol was infused 
during pre-ischemic and reperfusion period, PP group: PP188 was 
infused during pre-ischemic and reperfusion period. Baseline: 
immediately after stabilization, Tx: pre-ischemic treatment, R5: at 5 
minutes after reperfusion, R30: at 30 minutes after reperfusion, R60: 
at 60 minutes after reperfusion. Probability value was indicated as 
follows; *P < 0.05 vs. baseline, 
†vs. Tx, 
‡vs. R5, 
§vs. R30, 
∥vs. control 
group, 
¶vs. LP group, **vs. MP group. All groups demonstrated 
decreased values after reperfusion but there was no significant 
difference in dP/dtmax among the LP, MP and PP groups.362 www.ekja.org
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group: P < 0.001, LP group: P = 0004, MP group: P = 0.006). In 
the LP and MP groups, dP/dtmax gradually recovered after 5 
minutes of reperfusion. At 5, 30 and 60 minutes of reperfusion, 
dP/dtmax was significantly decreased in the PP group compared 
to the baseline values (P < 0.001). At 30 minutes of reperfusion, 
dP/dtmax was significantly higher in the PP group than in the 
control group, and at 60 minutes of reperfusion, dP/dtmax was 
significantly higher in the LP, MP and PP groups than in the 
control group (at 30 minutes of reperfusion: P = 0.020, at 60 
minutes of reperfusion: P = 0.006).
Coronary effluent flow rate (CEFR, Fig. 6)
In the LP group, CEFR gradually decreased after reperfusion, 
the values at 30 and 60 minutes of reperfusion were lower 
than the baseline and/or after pretreatment values (P = 0.003). 
During reperfusion periods, CEFR was higher in the LP group 
than in the control group (at 5 minutes of reperfusion: P < 
0.001, at 30 minutes of reperfusion: P = 0.008, at 60 minutes of 
reperfusion: P = 0.004). In the MP group and in the PP group 
also, CEFR gradually decreased during reperfusion periods and 
was lower than the baseline and/or after pretreatment values (P 
< 0.001 for the MP group and the PP group). The CEFR values 
in the MP group and in the PP group were numerically higher 
than those in the control group, and only the CEFR value at 5 
minutes of reperfusion was statistically significant (P < 0.001). 
Infarct size (Fig. 7)
Infarct size was significantly smaller in the LP, MP, and PP 
groups (14.27 ± 2.41%, 15.77 ± 2.40%, 14.40 ± 1.97%, respec-
tively) than in the control group (18.71 ± 2.42 %, P < 0.001). 
Discussion
In the current study, we examined the influence of MP on 
myocardial injury resulting from ischemia and reperfusion 
in an isolated rat heart model and compared the myocardial 
protective effects between MP and LP. From a hemodynamic 
point of view, LP and MP produced similar results except for 
transient differences in LVESP and HR. In the MP group, LVESP 
was higher and HR was lower than that in the LP group during 
reperfusion. Moreover, infarct size did not differ significantly 
between the MP group and the LP group, and there seemed 
to be little difference between LP and MP in their myocardial 
protective effects against ischemia-reperfusion injury.
Within the first few minutes of reperfusion after myocardial 
ischemia, bursts of oxygen free radicals are generated [15], and 
these have been implicated as a cause of deleterious effects on 
cellular membrane proteins that maintain ionic homeostasis 
[16]. The beneficial effect of LP lies on its free radical scavenging 
properties during myocardial ischemia and reperfusion 
[2]. In addition, LP acts as a calcium antagonist preventing 
Fig. 6. Coronary effluent flow rate. Values are expressed as mean ± 
SD. Control group: no treatment during pre-ischemic and reperfusion 
period, LP group: lipid emulsion propofol was infused during 
pre-ischemic and reperfusion period, MP group: microemulsion 
propofol was infused during pre-ischemic and reperfusion period, 
PP group: PP188 was infused during pre-ischemic and reperfusion 
period. Baseline: immediately after stabilization, Tx: pre-ischemic 
treatment, R5: at 5 minutes after reperfusion, R30: at 30 minutes after 
reperfusion, R60: at 60 minutes after reperfusion. Probability value 
was indicated as follows; *P < 0.05 vs. baseline, 
†vs. Tx, 
‡vs. R5, 
§vs. 
R30, 
∥vs. control group, 
¶vs. LP group, **vs. MP group. The coronary 
effluent flow rate was progressively decreased in all groups. However, 
in the LP group, the coronary effluent flow rate was significantly 
higher than that in the control group.
Fig. 7. Infarct sizes were calculated by using triphenyl tetrazolium 
staining method in all groups. Values are expressed as mean ± SD. 
Control group: no treatment during pre-ischemic and reperfusion 
period, LP group: lipid emulsion propofol was infused during 
pre-ischemic and reperfusion period, MP group: microemulsion 
propofol was infused during pre-ischemic and reperfusion period, 
PP group: PP188 was infused during pre-ischemic and reperfusion 
period. Probability value was indicated as follows; *P < 0.05 vs. 
control group. In the LP, MP and PP groups, the infarct size was 
significantly smaller than that in the control group. There were no 
significant differences in the infarct size between these three groups.363 www.ekja.org
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intracellular calcium overload which causes myocardial injury 
[3,17-19]. The cardioprotective effects of PP188, an emulsifying 
agent in MP were also evaluated. Animal models underwent 2 
hours of cardiopulmonary bypass with or without pretreatment 
with PP188. PP188 was associated with potentially beneficial 
changes in membrane protein expression, reduced capillary 
leakage, less hemodilution [7], and reduced membrane injury 
from ischemia and reperfusion [8,11].
In many previous studies, propofol and PP188 have been 
demonstrated to have myocardial protective effects, but to the 
best of our knowledge there is no report about cardioprotection 
by MP which consists of propofol and PP188. In our study, we 
evaluated whether propofol emulsified with PP188, MP, had an 
additive or synergistic cardioprotective effect against ischemia-
reperfusion injury. LP is known to have myocardial protective 
effect in the concentration range 25-100 μM (4.46-17.83 μg/
ml) in isolated rat hearts [1,2,12]. Clinically, the recommended 
propofol concentration is 3-6 μg/ml for general anesthesia. 
We chose a LP concentration of 6 μg/ml, this concentration has 
been clinically proven to be effective in myocardial protection 
against ischemia and reperfusion injury and falls in the 
recommended propofol concentration range. Protein binding 
of propofol ranges from 97 to 99% [20], and only a small fraction 
of administrated propofol exists as free propofol. However, not 
only free propofol in plasma but also propofol which is bound to 
protein or incorporated in cellular membrane can be effective 
in myocardial protection [1]. These findings mean that the total 
LP concentration in the perfusate solution, and not the free 
propofol concentration, is related to myocardial protection. The 
pharmacokinetics and pharmacodynamics of MP were similar 
to those of LP [14,21], and an MP concentration of 6 μg/ml was 
also used in the present study.
To compare infarct size in each group, we decided to use 
ischemic and reperfusion periods of 30 and 60 minutes, 
respectively. The ischemic and reperfusion periods were 
determined based on the previous studies. Infarct size reached 
its maximum after 35 minutes of global ischemia [22] and 
reperfusion for 60 minutes was optimal because the infarct 
appeared homogeneous at that time and did not become larger 
with longer reperfusion periods [23].
In the MP group, LVESP remains constant after initial 
stabilization but the heart rate was significantly reduced at 
5, 30 and 60 minutes of reperfusion. In the PP group, LVESP 
was maintained near baseline unlike that in the LP group, and 
HR recovered towards the baseline value after reperfusion. 
Constant LVESP in the MP group may enable other vital organs 
to maintain blood flow even after ischemia and reperfusion 
injury and the low heart rate may help reduce myocardial 
oxygen demand and subsequent recovery of the injured 
myocardium.
LVEDP in the LP group and in the MP group was significantly 
lower than that in the control group during early reperfusion 
period. The PP group showed increased LVEDP similar to that 
in the control group. These findings implicate that propofol 
decreased LVEDP, which was increased due to ischemia-
induced ventricular wall stiffness. This result is consistent with 
the previously reported propofol-induced myocardial protective 
effects [1]. In the MP group also, the LVEDP values were slightly 
higher than those in the LP group during reperfusion, but 
there were no statistically significant differences in LVEDP 
between the two groups. In all groups, LVEDP during the later 
reperfusion period was decreased towards the baseline values, 
and hence the long-term hemodynamic impact of PP188 could 
be negligible.
Infarct size in the LP, MP, and PP groups was smaller than 
that in the control group and infarct size did not differ between 
these 3 groups. Myocardial tissue edema can develop due to 
various pathologic conditions including myocardial ischemia, 
cardiopulmonary bypass, hypertension, and sepsis. Microvascular 
fluid loss is one of the leading causes of tissue edema, which 
contributes to cardiac dysfunction [24]. This damage to 
microvascular integrity is associated with loss of glycocalyx, 
reduction in the number of negatively charged molecules at the 
endothelial cell surface [25,26]. PP188 has membrane protecting 
effects by a sealing these damaged cell membranes [27]. This 
characteristic property of PP188 could produce myocardial 
protective effect against ischemia-reperfusion injury. According 
to our results, the infarct size in the MP group was similar to 
that in the LP group, even though MP consists of propofol and 
PP188. This finding demonstrated that PP188 did not interfere 
with the myocardial protective effects of propofol but it also did 
not have an additive or synergistic effect with propofol.
In terms of hemodynamics in this study, in the MP group, 
LVESP was maintained near baseline during the reperfusion 
period. But in the LP group, LVESP was lower than the baseline 
value during reperfusion. In the MP group, LVEDP remained 
close to the baseline during reperfusion unlike that in the LP 
group. These features are probably due to the nature of the 
emulsifier used in each propofol. Lipids are known to have 
no beneficial effects on myocardial protection from ischemia 
and reperfusion injury [28]. On the contrary, PP188 is known 
to have myocardial protective effects due to its cell membrane 
protecting effects [7-11]. However, the comparison between 
the MP group and the LP group revealed that hemodynamic 
parameters or infarct size were not significantly different 
between the two groups. In other words, the myocardial 
protective effect of MP was similar to that of LP, and this finding 
supported the conclusion that no additive cardioprotective 
effects were demonstrated with the use of MP. 
In conclusion, we demonstrated that MP administered 364 www.ekja.org
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before and after myocardial ischemia results in hemodynamic 
changes similar to those with LP, and the concentrations of MP 
required for achieving myocardial protective effects following 
ischemia and reperfusion also did not differ from those of 
LP. PP188 used as an emulsifying agent for MP did not any 
influence the myocardial protective effect of propofol in spite 
of its own myocardial protective effects. We suggest that MP 
with less lipid-related side effects can be more useful than LP in 
anesthesia for cardiac surgery.
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